A Prospective, Multicenter, Randomized, Noninferiority Trial of Stopad<sup>®</sup> Versus Tachosil<sup>®</sup> for Hemostasis After Liver Resection.

However, the difference in the proportion of subjects with a past history of surgical and interventional procedure did not reach statistical significance (22.64% for Stopad group; 9.80% for Tachosil group; p = 0.0768), and therefore it cannot be said that the significantly high incidence of adverse events in the Stopad group can be solely attributed to the higher proportion of subjects with past surgical/interventional history.

also in 111,027 other papers